Equities

Accolade Inc

Accolade Inc

Actions
Health CareHealth Care Providers
  • Price (USD)3.97
  • Today's Change-0.22 / -5.25%
  • Shares traded1.80m
  • 1 Year change-66.13%
  • Beta2.0031
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Accolade, Inc. provides personalized, technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. Its customers are primarily employers that deploy Accolade solutions in order to provide employees and their families with a single place to turn for their health, healthcare, and benefits needs. It also offers medical opinion services to commercial customers and virtual primary care and mental health support. Its platform, True Health Engine, combines open, cloud-based intelligent technology with multimodal support from a team of empathetic and knowledgeable Accolade Health Assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. Its offerings include Accolade Expert MD, Accolade Care, Plus and Connect and Accolade One.

  • Revenue in USD (TTM)431.53m
  • Net income in USD-88.99m
  • Incorporated2007
  • Employees2.40k
  • Location
    Accolade Inc660 W. Germantown Pike Suite 500PLYMOUTH MEETING 19462United StatesUSA
  • Phone+1 (610) 834-2989
  • Fax+1 (302) 636-5454
  • Websitehttps://www.accolade.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Longduoduo Co Ltd8.78m1.77m158.13m--89.23397.2876.3118.020.05910.05910.29230.01335.06453.60134.94--114.14------95.04--22.55--1.04--0.00--17.93--99.48------
ModivCare Inc2.77bn-160.74m169.60m21.20k--17.84--0.0612-11.31-11.31195.280.66751.60--7.57130,778.60-9.06-1.36-13.29-1.8315.7317.58-5.66-0.9619--0.39780.9919--9.8514.71-542.83--19.27--
Joint Corp120.07m-14.41m171.11m444.00--7.36--1.43-0.9743-0.97438.071.551.32--33.77270,430.40-15.864.32-23.506.0590.8290.28-12.003.68--1,156.170.0022--16.2426.27-1,656.09--35.09--
23andMe Holding Co.199.19m-631.48m172.04m560.00--1.20--0.8637-1.31-1.310.41120.28360.32158.2876.27355,692.80-101.91---130.54--44.7946.35-317.03-121.631.43--0.00---26.66-13.01-113.92---19.09--
Biodesix Inc60.90m-44.51m261.32m217.00--7.21--4.29-0.4613-0.46130.61440.24980.6296--8.55280,654.40-46.01-55.60-60.16-80.9477.5859.53-73.08-105.15---3.610.4971--28.4619.1620.32--106.31--
Viemed Healthcare Inc205.70m9.47m284.59m996.0031.312.388.361.380.23410.23415.083.071.3118.059.15206,525.106.0512.287.6415.5260.9562.574.6110.091.299.510.08810.0031.8223.2164.631.5033.67--
Airsculpt Technologies Inc193.03m-3.42m305.81m346.00--3.6039.631.58-0.0619-0.06193.361.480.9033--62.36557,875.80-1.60---1.81--65.39---1.77----2.620.4541--16.07--69.49------
Accolade Inc431.53m-88.99m313.00m2.40k--0.7191--0.7253-1.16-1.165.655.520.5253--15.98179,805.00-10.83-24.80-12.43-29.0447.4945.56-20.62-56.43----0.3242--14.0934.3078.29--31.97--
DocGo Inc742.84m30.09m356.06m2.92k12.541.127.670.47930.27760.27766.873.101.69--3.95254,832.406.62--9.30--32.97--3.92------0.1202--41.72---80.17------
Talkspace Inc172.54m-7.66m368.38m472.00--3.23--2.14-0.0458-0.04581.030.67821.26--17.28365,546.60-5.58---6.47--47.82---4.44------0.00--25.49--75.92------
Enhabit Inc1.04bn-8.80m404.78m10.80k--0.599316.870.3885-0.1756-0.175620.7813.430.7324--6.6496,472.22-0.478---0.540--48.80---0.6527----0.64380.4316---2.32---99.26------
Data as of Sep 20 2024. Currency figures normalised to Accolade Inc's reporting currency: US Dollar USD

Institutional shareholders

48.56%Per cent of shares held by top holders
HolderShares% Held
Brown Advisory LLCas of 31 Mar 20245.85m7.31%
ARK Investment Management LLCas of 30 Jun 20245.64m7.05%
The Vanguard Group, Inc.as of 31 Mar 20245.22m6.53%
BlackRock Fund Advisorsas of 31 Mar 20244.91m6.13%
Bellevue Asset Management AGas of 31 Mar 20244.80m6.01%
Rock Springs Capital Management LPas of 31 Mar 20243.54m4.43%
JPMorgan Investment Management, Inc.as of 31 Mar 20243.14m3.93%
JPMorgan Asset Management (UK) Ltd.as of 31 Mar 20242.04m2.56%
Nikko Asset Management Americas, Inc.as of 30 Jun 20242.01m2.52%
Geode Capital Management LLCas of 30 Jun 20241.70m2.12%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.